Unknown

Dataset Information

0

Droplet digital PCR quantification of miR-1290 as a circulating biomarker for pancreatic cancer.


ABSTRACT: Droplet digital PCR was used to validate miR-1290 as circulating biomarker for pancreatic cancer (PC). The diagnostic performance of miR-1290 was evaluate in 167 PC patients and 267 healthy subjects at clinical risk of developing the disease (HS). MiR-1290 plasma levels were compared to CA 19-9 determinations, and the combination of the two biomarkers was also taken into account. Plasma levels of miR-1290 were higher in PC patients compared to HS (p?=?2.55?×?10-16). A similar trend was observed for CA 19-9 determinations (p?=?1.03?×?10-47). ROC curve analysis revealed that miR-1290 in combination with CA 19-9 was effective for discriminating between PC patients and HS (AUC?=?0.956, 95% CI?=?0.933-0.979) than the two biomarkers tested alone (miR-1290: AUC?=?0.734, 0.678-0.789; CA 19-9: AUC?=?0.914, 0.877-0.951). The discriminating ability was higher when only PC patients with low or slightly increased CA 19-9 levels were compared with HS. MiR-1290 concentrations were not able to differentiate between PC patients with single or multiple risk factors for developing PC. Our data suggest that the absolute quantification of circulating miR-1290 levels does not allow to select patients at clinical risk of PC for entry into a surveillance program, and underline the methodological challenges still existing in utilizing circulating miRNAs as new promising biomarkers for PC.

SUBMITTER: Tavano F 

PROVIDER: S-EPMC6219528 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Droplet digital PCR quantification of miR-1290 as a circulating biomarker for pancreatic cancer.

Tavano Francesca F   Gioffreda Domenica D   Valvano Maria R MR   Palmieri Orazio O   Tardio Matteo M   Latiano Tiziana P TP   Piepoli Ada A   Maiello Evaristo E   Pirozzi Felice F   Andriulli Angelo A  

Scientific reports 20181106 1


Droplet digital PCR was used to validate miR-1290 as circulating biomarker for pancreatic cancer (PC). The diagnostic performance of miR-1290 was evaluate in 167 PC patients and 267 healthy subjects at clinical risk of developing the disease (HS). MiR-1290 plasma levels were compared to CA 19-9 determinations, and the combination of the two biomarkers was also taken into account. Plasma levels of miR-1290 were higher in PC patients compared to HS (p = 2.55 × 10<sup>-16</sup>). A similar trend wa  ...[more]

Similar Datasets

| S-EPMC6196277 | biostudies-literature
| S-EPMC5477260 | biostudies-other
| S-EPMC4118677 | biostudies-literature
| S-EPMC5396971 | biostudies-literature
| S-EPMC8164350 | biostudies-literature
| S-EPMC8517383 | biostudies-literature
| S-EPMC5567481 | biostudies-literature
| S-EPMC7243121 | biostudies-literature
| S-EPMC5234771 | biostudies-literature
| S-EPMC6013872 | biostudies-other